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role in refractory GERD patients. The purpose of this
cross-sectional survey study is to estimate the percentage
of patients actively treated with PPI’s (omeprazole and
lansoprazole), who perceive control of their symptoms.
The Gastrointestinal Symptom Rating Scale (GSRS), a
validated rating scale to assess GERD patients’ quality of
life, was utilized. The study hypothesis is that 80% of the
patients will perceive their symptom control is very good
or excellent. METHODS: An unblinded self-adminis-
tered questionnaire, including the GSRS, was mailed to
300 patients who were currently receiving GERD mainte-
nance therapy with a PPI. Patients were asked questions
regarding the duration and severity of symptoms, dosing
of medication, contributing lifestyle factors and debilita-
tion of disease. RESULTS: 153 questionnaires were re-
turned fully completed, a 51% response rate. The sur-
veyed patients were 60  14 years with 89% of
respondents being male. Of the PPI’s prescribed 86% and
14% were lansoprazole and omeprazole respectively. The
median total score of the GSRS was 19, representing mild
to moderate patient symptomatology. CONCLUSIONS:
66% of respondents treated with currently prescribed
PPI’s had very good or excellent symptom control, how-
ever the need exists for a more effective PPI for adequate
symptom control in 34% of patients.
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OBJECTIVE: Prescription drug formularies have been
used by many pharmacy benefit managers (PBMs) as a
tool to control the rising costs of prescription drugs and
became increasingly popular since the 1990s. Despite its
popularity, little is known about how familiar physicians
are with what prescriptions are on formulary. This study
examines factors associated with physician knowledge of
formulary. METHODS: The National Ambulatory Med-
ical Care Survey (NAMCS) is a data series of annual sur-
vey of a national representative sample of physician of-
fice visits. It provides up to six medications associated
with each office visit. The 1998 NAMCS collected infor-
mation regarding the formulary status (yes, no, do not
know, or not applicable) of each medication and pro-
vided a unique opportunities to assess physicians’ knowl-
edge of formulary. Univariate analyses as well as multi-
variate logit model were used to examine the association
between physician knowledge of formulary and types of
visits, physician specialty and practice locations. RE-
SULTS: On average, 47% of physicians did not know
whether the drug they prescribed was on formulary. Phy-
sicians whose patients belonged to an HMO and were
paid by capitation were seven times more likely to know
whether a drug was on formulary, compared to those
whose patients were neither in an HMO nor capitated.
Physicians in the South were 1.7 times more likely to
know than those in the West, whereas the odd-ratios was
0.7 for those in the Midwest. Neither physician specialty
(primary care physician versus specialist) nor patient his-
tory (new versus established patient) was found to be sig-
nificantly associated with physician knowledge of formu-
lary. CONCLUSIONS: It is important for PBMs to find
mechanisms to increase physician awareness of whether a
patient’s medications are on formulary. Improving physi-
cians’ understanding of what medications were on for-
mulary could potentially decrease prescription drug costs
for health care plans and patients.
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OBJECTIVES: To assess the association between hospi-
tal costs and the appropriateness of empirical antibiotic
treatment for community-acquired intra-abdominal in-
fection. METHODS: Patients were identified from hospi-
tal discharges from three hospitals for 1993 to 1997.
Medical records were obtained to validate the diagnosis
and obtain details of antibiotic therapy and its outcome.
Valid cases had macroscopic evidence of intra-abdominal
infection at operation, therefore all cases had surgical
control of infection in addition to antimicrobial therapy.
Appropriateness of empirical therapy was assessed from
the results of in-vitro sensitivity tests (culture positive
cases) and compliance with local antibiotic policies (cul-
ture negative cases). RESULTS: We identified 294 valid
cases of intra-abdominal infection of whom 162 (55%)
were culture positive. Appropriate antibiotic treatment
was associated with significantly shorter length of stay
and lower investigation costs for patients with positive
cultures but not for patients with negative cultures or no
test/result (data not shown). Culture ve cases, appropri-
ate (n  129) vs inappropriate (n  33): mean length of
stay 12 vs 22 days, p  0.0007 boot strap t test, mean in-
vestigation cost £250 vs £409 p  0.04, mean antibiotic
cost £138 vs £128 p  0.9. A log transformed linear re-
gression analysis was carried out on the cost data for the
culture positive cases adjusting for five independent vari-
ables. Inappropriate antibiotics, increasing age and a
higher number of comorbidities and previous admissions
were significantly associated with increased cost of hospi-
tal stay but not gender. This model accounted for 34% of
the variance in cost of hospital stay. For the cost of inves-
tigations inappropriate treatment, increasing age and
Abstracts 127
number of comorbidities were all significant predictors
accounting for 26% of variance in costs. Number of co-
morbidities was the only variable significantly associated
with the cost of antibiotics. CONCLUSIONS: Appropri-
ate empirical antibiotic treatment of patients with culture
positive intra-abdominal infection is strongly associated
with length of stay and hospital costs.
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OBJECTIVES: Historically, complication rates following
colorectal surgery were stratified by disease process, type
of operation, or anesthesia risk derived after an intensive
review of the medical record. Newer computer applica-
tions purport to shorten this process and predict the
probability of postoperative complications by distin-
guishing them from comorbidities that are co-mingled on
uniform discharge codes. We analyzed CaduCIS software
(CareScience, Inc., Philadelphia, PA) which uses dis-
charge codes to see if its predictions of comorbidity and
complications accurately track the medical record.
METHODS: Two-hundred and seventy patients were an-
alyzed using principal and secondary diagnoses coded on
discharge. Coding inaccuracies of clinical occurrences
were identified by physician review of each medical
record. The actual incidences of 17 common preoperative
comorbidities and 11 postoperative complications were
compared to computerized predictions by applying stan-
dard statistical tests. RESULTS: The overall incidence of
complications obtained by physician (actual) review was
47%, compared to 46% by computer. The computerized
predicted distribution of comorbidities was similar to the
actual occurrences in 15 of 17 categories. Analysis
showed a statistical difference between the computer-pre-
dicted and “actual” complication rates in 5 of the 11 cat-
egories; however these differences (underestimates) were
due to charting and coding inaccuracies, not to comput-
erized errors. The most common preoperative comorbidi-
ties and complications were cardiopulmonary (47% and
28%, respectively). CONCLUSIONS: The computer-sys-
tem’s accurate measurement of the overall complication
rate supports the claim that aggregate complication esti-
mates derived from readily available administrative data
are sufficient for across-the-board comparisons among
hospitals. The computerized system can generate such
measurements in a fraction of the time is takes to manu-
ally review the medical records. As uniform discharge
coding of co-mingled comorbidity and complications are
increasingly used to rapidly compute surgical outcomes,
colon and rectal surgeons need to ensure compatibility of
the actual and coded medical record.
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OBJECTIVES: Infliximab (Remicade) (I) 5mg/kg is effec-
tive to control refractory Crohn’s disease in 81% and to
improve fistulas in 68% of patients, thus greatly improv-
ing quality of life (QoL). The objective of this study was
to calculate the direct costs and savings generated by I to
achieve this improvement of QoL. METHODS: This mir-
ror-image study was carried out in 48 patients, of which
22 had fistulas, all responding to therapy. Patients were
followed for 6 to 24 months prior and 6 to 24 months af-
ter I. All direct costs to the Belgian public payer were re-
corded separately for every 6 month time period before
and after I, in order to control for a bias due to changed
management regardless of I. The cost of I was calculated
separately. IBDQ scores were recorded before and after I
for each period. RESULTS: There was an important
build up of costs in each period before I: 2–1.5y: 1,002
(459) Euro; 1.5–1.0y: 1,486 (459) Euro; 1.0–0.5:
2,114 (391) Euro; 0.5–0: 2,427 (302) Euro. After I
there was a sharp decrease of the cost of care (excluding
the cost of I) to 1,760 (239) Euro (00.5y) and 1,380
(264) Euro (0.51.0y). The decrease was statistically
significant (p0.016). The average cost of I in the first
six months was 4,850 (327) Euro and in the second six
months 1,300 (280) Euro. The IBDQ increased from
147.8 (SE 8.4) to 187.8 (SE 7.0). The total direct cost of
care after I, adjusted for the non-responders, was calcu-
lated to be 17.0 Euro per day of normalised QoL. CON-
CLUSIONS: Although the cost of infliximab is substan-
tial, the total direct cost to produce a normal QoL in the
entire year after therapy is quite acceptable, providing
that patients not responding are not further treated.
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Health-related quality of life (HRQoL) research suggests
that, due to unique characteristics of a disease state, dis-
ease specific tools are better discriminators of health sta-
tus than generic tools. OBJECTIVE: To compare generic
(SF-12) versus disease specific (SIBDQ) quality of life
tools in a cohort of patients receiving treatment for
Crohn’s Disease (CD). METHODS: Structural Equation
